世界のペプチド療法市場インサイト及び予測(非経口投与経路、粘膜投与経路、経口投与経路、経皮投与経路)

◆英語タイトル:Global Peptide Therapy Market Insights, Forecast to 2028

QYResearchが発行した調査報告書(QY22JLX10458)◆商品コード:QY22JLX10458
◆発行会社(リサーチ会社):QYResearch
◆発行日:2022年7月(※2025年版があります。お問い合わせください。)
◆ページ数:129
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,900 ⇒換算¥744,800見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD7,350 ⇒換算¥1,117,200見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD9,800 ⇒換算¥1,489,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

COVID-19のパンデミックにより、ペプチド療法のグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx%で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にペプチド療法の世界市場のxxx%を占める「非経口投与経路」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx%CAGRで成長すると予測されています。一方、「癌」セグメントは、この予測期間を通じてxxx%のCAGRに変更されます。
ペプチド療法の中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx%であり、中国とヨーロッパはそれぞれxxx%とxxx%です。中国の割合は2028年にxxx%に達し、対象期間を通じてxxx%のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx%、xxx%、xxx%になる見通しです。ヨーロッパのペプチド療法市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx%になる見通しです。

ペプチド療法のグローバル主要企業には、Eli Lilly、AstraZeneca、Merck、Ipsen、Novo Nordisk、Teva Pharmaceutical Industries、Abbott Laboratories、Sanofi、J & J、Novartis、Takeda、Ferring、AbbVie、Heinis、Hemmo、Emcure Pharmaceutical、Cipla、Gland Pharma、Troikaa Pharmaceuticals、Biological Eなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx%の市場シェアを占めています。

ペプチド療法市場は、種類と用途によって区分されます。世界のペプチド療法市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年~2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
非経口投与経路、粘膜投与経路、経口投与経路、経皮投与経路

【用途別セグメント】
癌、循環器疾患、消化器疾患、代謝性疾患、その他

【掲載地域】
北米:アメリカ、カナダ
ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋:日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米:メキシコ、ブラジル、アルゼンチン
中東・アフリカ:トルコ、サウジアラビア、UAE

【目次(一部)】

・調査の範囲
- ペプチド療法製品概要
- 種類別市場(非経口投与経路、粘膜投与経路、経口投与経路、経皮投与経路)
- 用途別市場(癌、循環器疾患、消化器疾患、代謝性疾患、その他)
- 調査の目的
・エグゼクティブサマリー
- 世界のペプチド療法販売量予測2017-2028
- 世界のペプチド療法売上予測2017-2028
- ペプチド療法の地域別販売量
- ペプチド療法の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別ペプチド療法販売量
- 主要メーカー別ペプチド療法売上
- 主要メーカー別ペプチド療法価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模(非経口投与経路、粘膜投与経路、経口投与経路、経皮投与経路)
- ペプチド療法の種類別販売量
- ペプチド療法の種類別売上
- ペプチド療法の種類別価格
・用途別市場規模(癌、循環器疾患、消化器疾患、代謝性疾患、その他)
- ペプチド療法の用途別販売量
- ペプチド療法の用途別売上
- ペプチド療法の用途別価格
・北米市場
- 北米のペプチド療法市場規模(種類別、用途別)
- 主要国別のペプチド療法市場規模(アメリカ、カナダ)
・ヨーロッパ市場
- ヨーロッパのペプチド療法市場規模(種類別、用途別)
- 主要国別のペプチド療法市場規模(ドイツ、フランス、イギリス、イタリア、ロシア)
・アジア太平洋市場
- アジア太平洋のペプチド療法市場規模(種類別、用途別)
- 主要国別のペプチド療法市場規模(日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア)
・中南米市場
- 中南米のペプチド療法市場規模(種類別、用途別)
- 主要国別のペプチド療法市場規模(メキシコ、ブラジル、アルゼンチン)
・中東・アフリカ市場
- 中東・アフリカのペプチド療法市場規模(種類別、用途別)
- 主要国別のペプチド療法市場規模(トルコ、サウジアラビア)
・企業情報
Eli Lilly、AstraZeneca、Merck、Ipsen、Novo Nordisk、Teva Pharmaceutical Industries、Abbott Laboratories、Sanofi、J & J、Novartis、Takeda、Ferring、AbbVie、Heinis、Hemmo、Emcure Pharmaceutical、Cipla、Gland Pharma、Troikaa Pharmaceuticals、Biological E
・産業チェーン及び販売チャネル分析
- ペプチド療法の産業チェーン分析
- ペプチド療法の原材料
- ペプチド療法の生産プロセス
- ペプチド療法の販売及びマーケティング
- ペプチド療法の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- ペプチド療法の産業動向
- ペプチド療法のマーケットドライバー
- ペプチド療法の課題
- ペプチド療法の阻害要因
・主な調査結果

Peptide therapy refers to restoring the amount of peptides to stimulate the cellular regeneration system in the body, and can be an excellent complement to small molecule and biotherapeutics as a treatment option under certain conditions. The most common uses of peptide therapy are to help build muscle and reduce fat, increase energy, improve sexual function, and reduce gastrointestinal and musculoskeletal inflammation. The most common prescription peptide combinations naturally boost growth hormone for better recovery. Peptides were initially used only for diagnostics and hormone therapy; however, as technology has advanced, they are now also widely used to treat cancer and chronic metabolic diseases. Peptides are also used in cosmeceutical operations to slow down the skin’s aging process.
Market Analysis and Insights: Global Peptide Therapy Market
Due to the COVID-19 pandemic, the global Peptide Therapy market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, Parenteral Route of Administration accounting for % of the Peptide Therapy global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Cancer segment is altered to an % CAGR throughout this forecast period.
China Peptide Therapy market size is valued at US$ million in 2021, while the US and Europe Peptide Therapy are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Peptide Therapy landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of Peptide Therapy include Eli Lilly, AstraZeneca, Merck, Ipsen, Novo Nordisk, Teva Pharmaceutical Industries, Abbott Laboratories, Sanofi and J & J, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Peptide Therapy Scope and Segment
Peptide Therapy market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Peptide Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Parenteral Route of Administration
Mucosal Route of Administration
Oral Route of Administration
Transdermal Route of Administration
Segment by Application
Cancer
Cardiovascular Diseases
Gastrointestinal Disorders
Metabolic Disorders
Others
By Company
Eli Lilly
AstraZeneca
Merck
Ipsen
Novo Nordisk
Teva Pharmaceutical Industries
Abbott Laboratories
Sanofi
J & J
Novartis
Takeda
Ferring
AbbVie
Heinis
Hemmo
Emcure Pharmaceutical
Cipla
Gland Pharma
Troikaa Pharmaceuticals
Biological E
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

❖ レポートの目次 ❖

1 Study Coverage
1.1 Peptide Therapy Product Introduction
1.2 Market by Type
1.2.1 Global Peptide Therapy Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Parenteral Route of Administration
1.2.3 Mucosal Route of Administration
1.2.4 Oral Route of Administration
1.2.5 Transdermal Route of Administration
1.3 Market by Application
1.3.1 Global Peptide Therapy Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Cancer
1.3.3 Cardiovascular Diseases
1.3.4 Gastrointestinal Disorders
1.3.5 Metabolic Disorders
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Peptide Therapy Sales Estimates and Forecasts 2017-2028
2.2 Global Peptide Therapy Revenue Estimates and Forecasts 2017-2028
2.3 Global Peptide Therapy Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Peptide Therapy Sales by Region
2.4.1 Global Peptide Therapy Sales by Region (2017-2022)
2.4.2 Global Sales Peptide Therapy by Region (2023-2028)
2.5 Global Peptide Therapy Revenue by Region
2.5.1 Global Peptide Therapy Revenue by Region (2017-2022)
2.5.2 Global Peptide Therapy Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Peptide Therapy Sales by Manufacturers
3.1.1 Global Top Peptide Therapy Manufacturers by Sales (2017-2022)
3.1.2 Global Peptide Therapy Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Peptide Therapy in 2021
3.2 Global Peptide Therapy Revenue by Manufacturers
3.2.1 Global Peptide Therapy Revenue by Manufacturers (2017-2022)
3.2.2 Global Peptide Therapy Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Peptide Therapy Revenue in 2021
3.3 Global Peptide Therapy Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Peptide Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Peptide Therapy Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Peptide Therapy Sales by Type
4.1.1 Global Peptide Therapy Historical Sales by Type (2017-2022)
4.1.2 Global Peptide Therapy Forecasted Sales by Type (2023-2028)
4.1.3 Global Peptide Therapy Sales Market Share by Type (2017-2028)
4.2 Global Peptide Therapy Revenue by Type
4.2.1 Global Peptide Therapy Historical Revenue by Type (2017-2022)
4.2.2 Global Peptide Therapy Forecasted Revenue by Type (2023-2028)
4.2.3 Global Peptide Therapy Revenue Market Share by Type (2017-2028)
4.3 Global Peptide Therapy Price by Type
4.3.1 Global Peptide Therapy Price by Type (2017-2022)
4.3.2 Global Peptide Therapy Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Peptide Therapy Sales by Application
5.1.1 Global Peptide Therapy Historical Sales by Application (2017-2022)
5.1.2 Global Peptide Therapy Forecasted Sales by Application (2023-2028)
5.1.3 Global Peptide Therapy Sales Market Share by Application (2017-2028)
5.2 Global Peptide Therapy Revenue by Application
5.2.1 Global Peptide Therapy Historical Revenue by Application (2017-2022)
5.2.2 Global Peptide Therapy Forecasted Revenue by Application (2023-2028)
5.2.3 Global Peptide Therapy Revenue Market Share by Application (2017-2028)
5.3 Global Peptide Therapy Price by Application
5.3.1 Global Peptide Therapy Price by Application (2017-2022)
5.3.2 Global Peptide Therapy Price Forecast by Application (2023-2028)
6 North America
6.1 North America Peptide Therapy Market Size by Type
6.1.1 North America Peptide Therapy Sales by Type (2017-2028)
6.1.2 North America Peptide Therapy Revenue by Type (2017-2028)
6.2 North America Peptide Therapy Market Size by Application
6.2.1 North America Peptide Therapy Sales by Application (2017-2028)
6.2.2 North America Peptide Therapy Revenue by Application (2017-2028)
6.3 North America Peptide Therapy Market Size by Country
6.3.1 North America Peptide Therapy Sales by Country (2017-2028)
6.3.2 North America Peptide Therapy Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Peptide Therapy Market Size by Type
7.1.1 Europe Peptide Therapy Sales by Type (2017-2028)
7.1.2 Europe Peptide Therapy Revenue by Type (2017-2028)
7.2 Europe Peptide Therapy Market Size by Application
7.2.1 Europe Peptide Therapy Sales by Application (2017-2028)
7.2.2 Europe Peptide Therapy Revenue by Application (2017-2028)
7.3 Europe Peptide Therapy Market Size by Country
7.3.1 Europe Peptide Therapy Sales by Country (2017-2028)
7.3.2 Europe Peptide Therapy Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Peptide Therapy Market Size by Type
8.1.1 Asia Pacific Peptide Therapy Sales by Type (2017-2028)
8.1.2 Asia Pacific Peptide Therapy Revenue by Type (2017-2028)
8.2 Asia Pacific Peptide Therapy Market Size by Application
8.2.1 Asia Pacific Peptide Therapy Sales by Application (2017-2028)
8.2.2 Asia Pacific Peptide Therapy Revenue by Application (2017-2028)
8.3 Asia Pacific Peptide Therapy Market Size by Region
8.3.1 Asia Pacific Peptide Therapy Sales by Region (2017-2028)
8.3.2 Asia Pacific Peptide Therapy Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Peptide Therapy Market Size by Type
9.1.1 Latin America Peptide Therapy Sales by Type (2017-2028)
9.1.2 Latin America Peptide Therapy Revenue by Type (2017-2028)
9.2 Latin America Peptide Therapy Market Size by Application
9.2.1 Latin America Peptide Therapy Sales by Application (2017-2028)
9.2.2 Latin America Peptide Therapy Revenue by Application (2017-2028)
9.3 Latin America Peptide Therapy Market Size by Country
9.3.1 Latin America Peptide Therapy Sales by Country (2017-2028)
9.3.2 Latin America Peptide Therapy Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Peptide Therapy Market Size by Type
10.1.1 Middle East and Africa Peptide Therapy Sales by Type (2017-2028)
10.1.2 Middle East and Africa Peptide Therapy Revenue by Type (2017-2028)
10.2 Middle East and Africa Peptide Therapy Market Size by Application
10.2.1 Middle East and Africa Peptide Therapy Sales by Application (2017-2028)
10.2.2 Middle East and Africa Peptide Therapy Revenue by Application (2017-2028)
10.3 Middle East and Africa Peptide Therapy Market Size by Country
10.3.1 Middle East and Africa Peptide Therapy Sales by Country (2017-2028)
10.3.2 Middle East and Africa Peptide Therapy Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Eli Lilly
11.1.1 Eli Lilly Corporation Information
11.1.2 Eli Lilly Overview
11.1.3 Eli Lilly Peptide Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Eli Lilly Peptide Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Eli Lilly Recent Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Corporation Information
11.2.2 AstraZeneca Overview
11.2.3 AstraZeneca Peptide Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 AstraZeneca Peptide Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 AstraZeneca Recent Developments
11.3 Merck
11.3.1 Merck Corporation Information
11.3.2 Merck Overview
11.3.3 Merck Peptide Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Merck Peptide Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Merck Recent Developments
11.4 Ipsen
11.4.1 Ipsen Corporation Information
11.4.2 Ipsen Overview
11.4.3 Ipsen Peptide Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Ipsen Peptide Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Ipsen Recent Developments
11.5 Novo Nordisk
11.5.1 Novo Nordisk Corporation Information
11.5.2 Novo Nordisk Overview
11.5.3 Novo Nordisk Peptide Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Novo Nordisk Peptide Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Novo Nordisk Recent Developments
11.6 Teva Pharmaceutical Industries
11.6.1 Teva Pharmaceutical Industries Corporation Information
11.6.2 Teva Pharmaceutical Industries Overview
11.6.3 Teva Pharmaceutical Industries Peptide Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Teva Pharmaceutical Industries Peptide Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Teva Pharmaceutical Industries Recent Developments
11.7 Abbott Laboratories
11.7.1 Abbott Laboratories Corporation Information
11.7.2 Abbott Laboratories Overview
11.7.3 Abbott Laboratories Peptide Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Abbott Laboratories Peptide Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Abbott Laboratories Recent Developments
11.8 Sanofi
11.8.1 Sanofi Corporation Information
11.8.2 Sanofi Overview
11.8.3 Sanofi Peptide Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Sanofi Peptide Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Sanofi Recent Developments
11.9 J & J
11.9.1 J & J Corporation Information
11.9.2 J & J Overview
11.9.3 J & J Peptide Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 J & J Peptide Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 J & J Recent Developments
11.10 Novartis
11.10.1 Novartis Corporation Information
11.10.2 Novartis Overview
11.10.3 Novartis Peptide Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Novartis Peptide Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Novartis Recent Developments
11.11 Takeda
11.11.1 Takeda Corporation Information
11.11.2 Takeda Overview
11.11.3 Takeda Peptide Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Takeda Peptide Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Takeda Recent Developments
11.12 Ferring
11.12.1 Ferring Corporation Information
11.12.2 Ferring Overview
11.12.3 Ferring Peptide Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Ferring Peptide Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Ferring Recent Developments
11.13 AbbVie
11.13.1 AbbVie Corporation Information
11.13.2 AbbVie Overview
11.13.3 AbbVie Peptide Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 AbbVie Peptide Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 AbbVie Recent Developments
11.14 Heinis
11.14.1 Heinis Corporation Information
11.14.2 Heinis Overview
11.14.3 Heinis Peptide Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Heinis Peptide Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Heinis Recent Developments
11.15 Hemmo
11.15.1 Hemmo Corporation Information
11.15.2 Hemmo Overview
11.15.3 Hemmo Peptide Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Hemmo Peptide Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Hemmo Recent Developments
11.16 Emcure Pharmaceutical
11.16.1 Emcure Pharmaceutical Corporation Information
11.16.2 Emcure Pharmaceutical Overview
11.16.3 Emcure Pharmaceutical Peptide Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 Emcure Pharmaceutical Peptide Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Emcure Pharmaceutical Recent Developments
11.17 Cipla
11.17.1 Cipla Corporation Information
11.17.2 Cipla Overview
11.17.3 Cipla Peptide Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.17.4 Cipla Peptide Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Cipla Recent Developments
11.18 Gland Pharma
11.18.1 Gland Pharma Corporation Information
11.18.2 Gland Pharma Overview
11.18.3 Gland Pharma Peptide Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.18.4 Gland Pharma Peptide Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.18.5 Gland Pharma Recent Developments
11.19 Troikaa Pharmaceuticals
11.19.1 Troikaa Pharmaceuticals Corporation Information
11.19.2 Troikaa Pharmaceuticals Overview
11.19.3 Troikaa Pharmaceuticals Peptide Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.19.4 Troikaa Pharmaceuticals Peptide Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.19.5 Troikaa Pharmaceuticals Recent Developments
11.20 Biological E
11.20.1 Biological E Corporation Information
11.20.2 Biological E Overview
11.20.3 Biological E Peptide Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.20.4 Biological E Peptide Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.20.5 Biological E Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Peptide Therapy Industry Chain Analysis
12.2 Peptide Therapy Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Peptide Therapy Production Mode & Process
12.4 Peptide Therapy Sales and Marketing
12.4.1 Peptide Therapy Sales Channels
12.4.2 Peptide Therapy Distributors
12.5 Peptide Therapy Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Peptide Therapy Industry Trends
13.2 Peptide Therapy Market Drivers
13.3 Peptide Therapy Market Challenges
13.4 Peptide Therapy Market Restraints
14 Key Findings in The Global Peptide Therapy Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のペプチド療法市場インサイト及び予測(非経口投与経路、粘膜投与経路、経口投与経路、経皮投与経路)(Global Peptide Therapy Market Insights, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。